Asset Details
Do you wish to reserve the book?
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
Do you wish to request the book?
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
2019
Overview
Background
While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF). While AFF has been reported in patients with osteoporosis receiving denosumab, data are scarce in the context of AFF occurring in patients with bone metastasis receiving monthly denosumab therapy.
Methods
To analyze the incidence of AFF in patients with bone metastasis, we reviewed the medical records of patients who had received monthly denosumab (120 mg) treatment from May 2012 to June 2017 at any of the three participant institutions.
Results
The study population consisted of 277 patients who had received a median of 10 doses (range, 1–79) of denosumab. Five patients were diagnosed as having AFF or symptomatic atypical femoral stress reaction (AFSR) needing surgical intervention, representing an incidence rate of 1.8% (95% confidence interval, 0.77–4.2). These patients had received 15, 45, 45, 46 or 47 doses of denosumab, respectively. Four of the patients had received prior zoledronic acid treatment. The results of our analysis suggested that long-term use of denosumab, especially for more than 3.5 years, and prior use of zoledronic acid were risk factors for the development of AFF.
Conclusions
We found the AFF events in 5 patients (1.8%) among 277 cancer patients who had received monthly denosumab (120 mg) treatment. Long-term denosumab treatment and prior zoledronic acid treatment were identified as risk factors for the development of AFF.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Aged
/ Biomedical and Life Sciences
/ Bone Density Conservation Agents - administration & dosage
/ Bone Density Conservation Agents - adverse effects
/ Bone Density Conservation Agents - therapeutic use
/ Bone Neoplasms - drug therapy
/ Cancer
/ Denosumab - administration & dosage
/ Female
/ Femoral Fractures - epidemiology
/ Femoral Fractures - pathology
/ Health Promotion and Disease Prevention
/ Humans
/ Male
/ Medical and radiation oncology
/ Oncology
